Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2011-07-19
2011-07-19
Chu, Yong (Department: 1622)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S326000, C514S415000, C546S201000, C544S143000, C548S483000
Reexamination Certificate
active
07981888
ABSTRACT:
Compounds of Formula Iwherein A1, B1, C1, D1, E1, F1and L1are as defined herein, which inhibit the activity of anti-apoptotic Mcl-1 protein, compositions containing the compounds, and methods of treating diseases involving overexpressed or unregulated Mcl-1 protein, such as leukemia and lymphoma, are disclosed.
REFERENCES:
patent: 4994477 (1991-02-01), Kempf
patent: 6787651 (2004-09-01), Stolle et al.
patent: 7268159 (2007-09-01), Hu et al.
patent: 2006/0160879 (2006-07-01), Olofsson et al.
patent: 2006041961 (2006-04-01), None
patent: 2006/061493 (2006-06-01), None
Amundson, Sally, “An Informatics approach Identifying Markers of Chemosensitivity in Human Cancer Cell Lines”, Cancer Research, vol. 60, pp. 6101-6110, Nov. 2000.
Backus, Annals of Oncology: Official Journal of the European Society for Medical Oncology/ESMO 2001, vol. 12, pp. 779-785, 2001.
Baekelandt, M., “Expression of apoptosis-Related Proteins Is an Independent Determinant of Patient Prognosis in Advanced Ovarian Cancer”, J Clin. Oncol., vol. 18, pp. 3775-3781, 2000.
Chung, T, “Expression of apoptotic regulators and their significance in cervical cancer”, Cancer Letters, vol. 180, pp. 63-68, 2002.
Deininger, Martin, “Antiapoptotic Bcl-2 Family Protein Expression Increases with Progression of Oligodendroglioma”, Cancer, vol. 86, pp. 1832-1839, 1999.
Eerola, A-K, “Accelerated Apoptosis and Low Bcl-2 Expression Associated with Neuroendocrine Differentiation Predict Shortened Survival in Operated Large Cell Carcinoma of the Lung”, Pathology Oncology Research, vol. 5, pp. 179-186, 1999.
Fong, P., “Mcl-1 Expression in Gestational Trophoblastic Disease Correlates with Clinical Outcome”, Cancer, vol. 103, pp. 268-276, 2005.
Gomez-Bougie, P., “The imbalance between Bim and Mcl-1 expression controls the survival of human myeloma cells”, Eur. J. Immunol., vol. 34, pp. 3156-3164, 2004.
Greene, T.H. and P.G.M. Wuts, “Protective Groups in Organic Synthesis”, 3rd E., John Wiley & Sons, New York, pp. 246-292, 1999.
Holzelova, E., “Autoimmune Lymphoproliferative Syndrome with Somatic Fas Mutations”, New England Journal of Medicine, vol. 351, pp. 1409-1418, 2004.
Hotz, M., “Spontaneous Apoptosis and the Expression of p53 and Bcl-2 Family Proteins in Locally Advanced Head and Neck Cancer”, Archives of Otolaryngology-Head and Neck Surgery, vol. 125, pp. 417-422, 1999.
IUPAC Commission on Nomenclature of Organic Chemistry, Pure Appl. Chem., vol. 45, pp. 10-13, 1976.
Kaufmann, S.H., “Elevated Expression of the Apoptotic Regulator Mcl-1 at the Time of Leukemic Relapse”, Blood, vol. 91, pp. 991-1000, 1998.
Kuramoto, K., “High expression of MCL1 gene related to vascular endothelial growth factor is associated with poor outcome in non-Hodgkin's lymphoma”, British J. of Haematology, vol. 116, pp. 158-161, 2002.
Maeta, Y., “Expression of Mcl-1 and p53 proteins predicts the survival of patients with T3 gastric carcinoma”, Gastric Cancer, vol. 7, pp. 78-84, 2004.
Moshynska, O., “Prognostic Significance of a Short Sequence Insertion in the McL-1 Promoter in Chronic Lymphocytic Leukemia”, J. of the National Cancer Institute, vol. 96, pp. 673 to 682, 2004.
Packham, G., “Bodyguards and assassins: Bcl-2 family proteins and apoptosis control in chronic cymphocytic leukaemia”, Immunology, vol. 114, pp. 441-449, 2005.
Puck, J., “Immune disorders caused by Defects in the Caspase Cascade”, Current Allergy and Asthma Reports, vol. 3, pp. 378-384, 2003.
Rassidakis, G., “BCL-2 family proteins in peripheral T-cell lymphomas: correlation with tumour apoptosis and proliferation”, Journal of Pathology, vol. 200, pp. 240-248, 2003.
Shi, X, “Acquired Resistance of Pancreatic Cancer Cells towards 5-Fluorouracil and gemcitabine is Associated with Altered Expression of Apoptosis-Regulating Genes”, Oncology, vol. 62, pp. 354-362, 2002.
Shimazaki, K., “Evaluation of apoptosis as a prognostic factor in myelodysplastic syndromes”, Br. J. Haematol. , vol. 110(3), pp. 584-591, 2000.
Soini, Y., “Apoptosis and Expression of Apoptosis Regulating Proteins bcl-2, mcl-1, bcl-X, and bax in Malignant Mesothelioma”, Clinical Cancer Research, vol. 5, pp. 3508-3515, 1999.
Strik, H , “BCL-2 Family protein expression in initial and recurrent gliobastomas: modulation by radiochemotherapy”, J. Neurol. Neurosurg. Psychiatry, vol. 67, pp. 763-768, 1999.
Tsuji, J., “Palladium Reagents and Catalysts: New Perspectives for the 21st Century”, John Wiley & Sons, Ltd. Chichester, pp. 1-670, 2004.
8798WOO1 PCT Search Report and Written Opinion (PCT/US2008/060427) mailed Nov. 20, 2009.
Bruncko Milan
Ding Hong
Elmore Steven W.
Kunzer Aaron R.
Madar David J.
Abbott Laboratories
Chu Yong
Jones Day
Rodriguez-Garcia Valerie
LandOfFree
1-oxyalkyl-2-carboxyl-7-nonsubstituted indole derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 1-oxyalkyl-2-carboxyl-7-nonsubstituted indole derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 1-oxyalkyl-2-carboxyl-7-nonsubstituted indole derivatives will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2687696